AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$PRTA

SCULLY WILLIAM P purchased $256K of PRTA

SCULLY WILLIAM P purchased 27,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $9.47 ($0.26M total) on 2026-09-02.

Original reporting
SEC EDGAR · SCULLY WILLIAM P
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PRTA
Neutral
medium confidence
Mentioned
$PRTA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRTANeutralLow
01

Why it matters

The filing adds a fresh data point on insider ownership, but the monetary size is small.

02

Market read

New insider purchase provides a modest signal of confidence but unlikely to affect market pricing.

03

What to watch

Potential upcoming catalyst not disclosed; insider may have material non‑public information.

Relevance 5/10Novelty 4/10Timing: today

Background

Form 4 filing discloses insider transactions to the SEC; such filings are primary sources of new information.

Company-level read

Ticker impact

$PRTANeutralMedium confidence
Context

Insider S.CULLY purchased 27,000 shares of Prothena at $9.47, total $255,739, increasing holdings to 827,000 shares.

Expected impact

Limited upside pressure; unlikely to move price materially.

Evidence & confidence

Purchase amount (~$0.25M) is minor for a listed biotech; market may view it as a routine transaction.

Market effects

Sector

Minimal impact on biotech sector; insider activity is routine.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The purchase could be a strategic move ahead of upcoming clinical data, suggesting upside.

Key entities

  • Company
    Prothena Corp Public Ltd Co

    Biotech firm listed on NASDAQ under ticker PRTA.

  • Insider
    S. CULLY

    10% owner filing a purchase of 27,000 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PRTA insider trading history →

Related articles

AUG 7
$PRTAMed

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.

tradingview.com7 min
AUG 6
$PRTAMed

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provided by operating and investing activities was $3.2 million f

SEC EDGAR 8-K6 min
SEP 29
$COURMedAI 8/10

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $11.4M of COUR (indirect holdings)

Pale Fire Capital SE purchased 2,332,742 indirectly-held shares of Coursera, Inc. (COUR) at an average of $4.87 ($4.61–$5.06, $11.36M total) across 2 trades over 2026-09-25 to 2026-09-29. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min